Long term safety of QGE031 in allergic asthma patients

• Research type

  Research Study

• Full title

  An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201

• IRAS ID

  150048

• Contact name

  Fosca De iorio

• Contact email

  fosca.de_iorio@novartis.com

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2013-003683-31

• Clinicaltrials.gov Identifier

  NCT02075008

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  14/SC/0184

• Date of REC Opinion

  27 May 2014

• REC opinion

  Further Information Favourable Opinion